The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-27. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
==== Minor sources ==== Volcanic eruptions may emit PAHs. Certain PAHs such as perylene can also be generated in anaerobic sediments from existing organic material, although it remains undetermined whether abiotic or microbial processes drive their production.
=== NMR spectroscopy === Poly-γ-benzyl-L-glutamate (PBLG), a glutamic acid derivative, is often used as an alignment medium to control the scale of the dipolar interactions observed in the use of residual dipolar coupling (RDC) in nuclear magnetic resonance spectroscopy (NMR).
{\displaystyle {\begin{aligned}\int \delta \varepsilon &=\int _{L}^{l}{\frac {\delta l}{l}}\\\varepsilon &=\ln \left({\frac {l}{L}}\right)=\ln(\lambda )\\&=\ln(1+e)\\&=e-{\frac {e^{2}}{2}}+{\frac {e^{3}}{3}}-\cdots \end{aligned}}}
== Description == The blue mackerel typically reaches 30 cm (12 in) in fork length. It can reach 44 cm (17 in) in fork length and 1.4 kg (3.1 lb) in weight. Mackerels have a round body that narrows into the tail after the second dorsal fin, similar to a tuna fish. Blue mackerel are often mistaken for chub mackerel. In fact, blue mackerel were believed to be a subspecies of chub mackerel until the late 1980s. Though they are both in the same genus (Scomber), blue mackerel set themselves apart by differing structural genes than those of the chub mackerel. Other, more obvious, characteristics set these two apart, like the longer anal spine of the blue mackerel, and the amount of spines on the first dorsal fin.
Sources: en.wikipedia.org
Moreover, the Australian High Court is behind international standards by refusing to accept that employment is shaped by unequal bargaining power, or carries a duty of mutual trust and confidence, even a similar duty is accepted for commercial franchising and distribution agreements. In Commonwealth Bank of Australia Ltd v Barker the High Court held there was no duty of mutual trust and confidence because employment is already heavily regulated by statute, which led to their conclusion that fair treatment in redundancy was not implied. By contrast, under the Independent Contractors Act 2006 section 12 explicitly states courts have the power to review and vary independent contractors' contracts if they are unfair, given their unequal bargaining power and lack of other statutory rights. Terms may also be implied by custom 'so well known and acquiesced in that everyone making a contract... can reasonably be presumed to have imported that term into the contract.'
=== Patient information === Blood Transfusion Leaflets (NHS Blood and Transplant) Blood Transfusion Leaflets (Welsh Blood Service) Blood Transfusion Information (Scotland) Blood Transfusion Information (Australia) Blood Transfusion Information (American Cancer Society)
chromocenter A central amorphous mass of polytene chromosomes found in the nuclei of cells of the salivary glands in Drosophila larvae and resulting from the fusion of heterochromatic regions surrounding the centromeres of the somatically paired chromosomes, with the distal euchromatic arms radiating outward.
=== Transportation and detoxification === This could happen in two different ways: ammonia itself might simply diffuse (as NH3) or be transported (as NH4+) across the cell membranes in and out of the extracellular space, or a shuttle system involving carrier molecules (amino acids) might be employed. Certainly, ammonia can diffuse across lipid membranes, and it has been shown that ammonia can be transported by K+/Cl− co-transporters.
Meanwhile, in 1843, James Prescott Joule independently discovered the mechanical equivalent in a series of experiments. In one of them, now called the "Joule apparatus", a descending weight attached to a string caused a paddle immersed in water to rotate. He showed that the gravitational potential energy lost by the weight in descending was equal to the internal energy gained by the water through friction with the paddle. Over the period 1840–1843, similar work was carried out by engineer Ludwig A. Colding, although it was little known outside his native Denmark. Both Joule's and Mayer's work suffered from resistance and neglect but it was Joule's that eventually drew the wider recognition.
Sources: en.wikipedia.org
=== Acquisitions === Grifols acquired its first group of plasma donation centers (43 in the U.S.) in 2002, taking over the company SeraCare, now known as Biomat. The following year, Grifols acquired Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles, California. In 2011, Grifols acquired the North American company Talecris Biotherapeutics, making Grifols the third-largest manufacturer of plasma-derived medicines in the world. Grifols acquired Novartis' blood transfusion diagnostics unit, based in Emeryville, California, in 2014. It was a part of Chiron, which had been acquired by Novartis in 2006. Grifols grew its transfusion medicine business with the acquisition of Hologic’s transfusion unit in 2017, leading the company’s creation of reagents and instrumentation based on NAT (nucleic acid testing) technology. In 2018, Grifols acquired the German company Haema and its network of donation centers and, in 2019, Grifols grew its network of donation centers with the addition of Interstate Blood Bank Inc. Today, the company has approximately 400 donation centers worldwide, most of them located in the U.S. Following a major equity investment in 2015, Grifols acquired the remaining shares of Alkahest in 2020 to help enhance the company’s discovery research and development to identify therapies based upon an understanding of the human plasma proteome. In 2021, the company acquired the remaining capital of GigaGen, a U.S.
== Legacy == Allitt was the subject of a book called Murder on Ward Four by Nick Davies. A BBC dramatisation of the case, Angel of Death (2005), featured Charlie Brooks as Allitt. Allitt's story was depicted in episodes of the true crime documentaries Crimes That Shook Great Britain, Deadly Women, Born To Kill?, Evil Up Close, Britain's Most Evil Killers, and Nurses Who Kill. Commentators drew comparisons between convicted murderer Lucy Letby and the Allitt case. The former detective who led the Allitt investigation suggested that Letby might have imitated Allitt's methods. Criminal psychologists Dominic Wilmott and David Holmes proposed that Letby could have been motivated by factitious disorder imposed on another, a theory also raised in relation to Allitt.31:15
=== As an androgen === DHEA and other adrenal androgens such as androstenedione, although relatively weak androgens, are responsible for the androgenic effects of adrenarche, such as early pubic and axillary hair growth, adult-type body odor, increased oiliness of hair and skin, and mild acne. DHEA is potentiated locally via conversion into testosterone and dihydrotestosterone (DHT) in the skin and hair follicles. Women with complete androgen insensitivity syndrome (CAIS), who have a non-functional androgen receptor (AR) and are immune to the androgenic effects of DHEA and other androgens, have absent or only sparse/scanty pubic and axillary hair and body hair in general, demonstrating the role of DHEA and other androgens in body hair development at both adrenarche and pubarche.
Polonium in the body has a biological half-life of about 30 to 50 days. Caesium in the body has a biological half-life of about one to four months. Mercury (as methylmercury) in the body has a half-life of about 65 days. Lead in the blood has a half-life of 28–36 days. Lead in bone has a biological half-life of about ten years. Cadmium in bone has a biological half-life of about 30 years. Plutonium in bone has a biological half-life of about 100 years. Plutonium in the liver has a biological half-life of about 40 years.
A mass spectrometer resolves the m/z of particles, where m is the accurate mass. As one can glance from the monoisotopic masses, the two molecules are very close in weight. When using a insufficiently powerful mass spectrometer such as a quadrupole mass analyser or a quadrupolar ion trap, the two molecules will show their m/z peaks blended together into one peak. If a high-resolution instrument like an orbitrap or an ion cyclotron resonance is used, these two molecules can be distinguished. The nominal mass is much easier to calculate than the exact monoisotopic mass and serves as an approximation of it. When two particles have the same nominal mass, their monoisotopic masses are usually too close to each other to be resolved using low-resolution instrument. The added precision of monoisotopic mass is very useful when analyzing small organic compounds since compounds with similar weights will not be differentiated if the nominal mass is used. For example, when comparing tyrosine which has a molecular structure of C9H11NO3 with a monoisotopic mass of 182.081 Da and methionine sulphone C5H11NO4S which clearly are 2 different compounds but methionine sulphone has a 182.048 Da.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.